Evidence map›Paper›PMID 30562343›Full record

ArticlePloS one2018

Identification of alterations in macrophage activation associated with disease activity in systemic lupus erythematosus.

Adam C Labonte, Brian Kegerreis, Nicholas S Geraci, Prathyusha Bachali, Sushma Madamanchi, Robert Robl, Michelle D Catalina, Peter E Lipsky, Amrie C Grammer

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 111 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Exploring the Efficacy and Target Genes ofCurrent issues in molecular biology · 2025
    Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Adam C LabonteAMPEL BioSolutions LLC, Charlottesville, Virginia, United States of America.ORCID 0000-0001-7378-2638
Brian KegerreisAMPEL BioSolutions LLC, Charlottesville, Virginia, United States of America.
Nicholas S GeraciAMPEL BioSolutions LLC, Charlottesville, Virginia, United States of America.
Prathyusha BachaliAMPEL BioSolutions LLC, Charlottesville, Virginia, United States of America.
Sushma MadamanchiRILITE Research Institute, Charlottesville, Virginia, United States of America.
Robert RoblRILITE Research Institute, Charlottesville, Virginia, United States of America.
Michelle D CatalinaAMPEL BioSolutions LLC, Charlottesville, Virginia, United States of America.
Peter E LipskyAMPEL BioSolutions LLC, Charlottesville, Virginia, United States of America.
Amrie C GrammerAMPEL BioSolutions LLC, Charlottesville, Virginia, United States of America.
Ampel BioSolutions (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is characterized by abnormalities in B cell and T cell function, but the role of disturbances in the activation status of macrophages (Mϕ) has not been well described in human patients. To address this, gene expression profiles from isolated lymphoid and myeloid populations were analyzed to identify differentially expressed (DE) genes between healthy controls and patients with either inactive or active SLE. While hundreds of DE genes were identified in B and T cells of active SLE patients, there were no DE genes found in B or T cells from patients with inactive SLE compared to healthy controls. In contrast, large numbers of DE genes were found in myeloid cells (MC) from both active and inactive SLE patients. Among the DE genes were several known to play roles in Mϕ activation and polarization, including the M1 genes STAT1 and SOCS3 and the M2 genes STAT3, STAT6, and CD163. M1-associated genes were far more frequent in data sets from active versus inactive SLE patients. To characterize the relationship between Mϕ activation and disease activity in greater detail, weighted gene co-expression network analysis (WGCNA) was used to identify modules of genes associated with clinical activity in SLE patients. Among these were disease activity-correlated modules containing activation signatures of predominantly M1-associated genes. No disease activity-correlated modules were enriched in M2-associated genes. Pathway and upstream regulator analysis of DE genes from both active and inactive SLE MC were cross-referenced with high-scoring hits from the drug discovery Library of Integrated Network-based Cellular Signatures (LINCS) to identify new strategies to treat both stages of SLE. A machine learning approach employing MC gene modules and a generalized linear model was able to predict the disease activity status in unrelated gene expression data sets. In summary, altered MC gene expression is characteristic of both active and inactive SLE. However, disease activity is associated with an alteration in the activation of MC, with a bias toward the M1 proinflammatory phenotype. These data suggest that while hyperactivity of B cells and T cells is associated with active SLE, MC potentially direct flare-ups and remission by altering their activation status toward the M1 state.

Indexed as

Computational BiologyDatasets as TopicGene Expression ProfilingGene Expression RegulationGene Regulatory NetworksHumansLupus Erythematosus, SystemicMachine LearningMacrophage ActivationMacrophagesSymptom Flare UpTranscriptome

Identifiers

PMID30562343
PMCPMC6298676
OpenAlexW2904379191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.